RELMADA THERAPEUTICS, INC.
RLMDDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How RLMD's past catalysts played out
REL-1017
Depressive Disorder, Major
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Non Muscle Invasive Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
REL-1017 | Phase 3 | Depressive Disorder, Major | - | - |
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Phase 2 | Non Muscle Invasive Bladder Cancer | - | - |
Frequently asked questions
What is in RELMADA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in RELMADA THERAPEUTICS, INC.'s (RLMD) pipeline across Phase 3, Phase 2. Its lead program is REL-1017 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is RELMADA THERAPEUTICS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for RELMADA THERAPEUTICS, INC. (RLMD) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RLMD biotech catalysts?→
Add RLMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow RELMADA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.